End-of-life care utilizes a great deal of health resources and accounts for a large percent of all health care spending. Palliative care at the end-of-life is an approach designed to both improve patient care and lower costs. A review article in Palliative Medicine examines the research literature on palliative care’s cost effects. (Pall. Med. Article) Like many interventions, palliative care covers a variety of techniques in a variety of settings performed by a variety of providers. This diversity makes good research and research comparisons difficult. As the name suggests, the common aim of palliative care is not to treat or improve a health care condition or illness, nor to stave off decline and ultimate death, but rather to ensure the patient’s comfort and maximize their quality of life at the end. After an exhaustive literature search, the authors found 46 studies that fit their criteria. Most were not randomized trials, but had other indicia of reliability. In the randomized trials, costs for palliative care patients were generally lower than those for patients receiving usual care. Much of the savings appears attributable to less use of hospital inpatient services. In cohort studies, palliative care again usually showed lower utilization and spending than usual care. Several of these studies evaluated hospice care, finding that it lower Medicare spending. In studies looking at hospital-based palliative care, significantly lower spending was found in most cases. Overall, one might conclude that palliative care results in decreased health utilization and spending compared to non-palliative care, but there are inconsistencies in the results. Only one study looked at cost-effectiveness, which is aimed more at discerning the value of care per unit of cost. This study showed palliative care appeared to achieve the same or better outcomes for a lower cost, most of the time. Other research has usually found that palliative care in particular improved patient-centered outcomes; that is, it raised the quality of life and satisfaction of patients. This should be the most important consideration.
By Kevin RocheFebruary 12, 2014Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 21, 2023
Minnesota’s New Energy Insanity, Part 7
Minnesota is a particularly poor place to rely on solar power, but other states aren't…
March 21, 2023
A Quick SVB Follow-up
As I suspected, the SVB saga is primarily one of regulatory malfeasance, coupled with political…
March 19, 2023
Tom Frieden Speaks in the WSJ
A public health expert writes an article for the WSJ which amply demonstrates why Americans…